Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1259 (LINC01259) is a member of the long intergenic non-coding RNA (lincRNA) family, defined as autonomously transcribed RNA molecules longer than 200 nucleotides that do not overlap coding genes[1][3]. LINC01259 does not code for a protein but may regulate gene expression through mechanisms such as chromatin remodeling, transcriptional regulation, and providing enhancer-like activity[3]. LincRNAs often have tissue-specific functions, and while a minority have well-described cellular roles, the majority—including LINC01259—remain poorly characterized in terms of specific biological or disease roles[3][5]. There are currently no known therapies or drugs directly targeting LINC01259, and it is not established as a clinical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1259 (LINC01259).